137 related articles for article (PubMed ID: 22129918)
1. Targeting the oncogene eIF4E in cancer: From the bench to clinical trials.
Borden KL
Clin Invest Med; 2011 Dec; 34(6):E315. PubMed ID: 22129918
[TBL] [Abstract][Full Text] [Related]
2. Ribavirin as an anti-cancer therapy: acute myeloid leukemia and beyond?
Borden KL; Culjkovic-Kraljacic B
Leuk Lymphoma; 2010 Oct; 51(10):1805-15. PubMed ID: 20629523
[TBL] [Abstract][Full Text] [Related]
3. Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin.
Assouline S; Culjkovic B; Cocolakis E; Rousseau C; Beslu N; Amri A; Caplan S; Leber B; Roy DC; Miller WH; Borden KL
Blood; 2009 Jul; 114(2):257-60. PubMed ID: 19433856
[TBL] [Abstract][Full Text] [Related]
4. Suppression of oncogenic protein translation via targeting eukaryotic translation initiation factor 4E overcomes chemo-resistance in nasopharyngeal carcinoma.
Xu M; Tao Z; Wang S; Jiang Y; Qu M
Biochem Biophys Res Commun; 2019 May; 512(4):902-907. PubMed ID: 30929914
[TBL] [Abstract][Full Text] [Related]
5. The eukaryotic translation initiation factor eIF4E in the nucleus: taking the road less traveled.
Osborne MJ; Borden KL
Immunol Rev; 2015 Jan; 263(1):210-23. PubMed ID: 25510279
[TBL] [Abstract][Full Text] [Related]
6. Eukaryotic translation initiation factor 4E as a novel therapeutic target in hematological malignancies and beyond.
Pettersson F; Del Rincon SV; Miller WH
Expert Opin Ther Targets; 2014 Sep; 18(9):1035-48. PubMed ID: 25004955
[TBL] [Abstract][Full Text] [Related]
7. Targeting eukaryotic translation initiation factor 4E (eIF4E) in cancer.
Hsieh AC; Ruggero D
Clin Cancer Res; 2010 Oct; 16(20):4914-20. PubMed ID: 20702611
[TBL] [Abstract][Full Text] [Related]
8. Targeting EIF4E signaling with ribavirin in infant acute lymphoblastic leukemia.
Urtishak KA; Wang LS; Culjkovic-Kraljacic B; Davenport JW; Porazzi P; Vincent TL; Teachey DT; Tasian SK; Moore JS; Seif AE; Jin S; Barrett JS; Robinson BW; Chen IL; Harvey RC; Carroll MP; Carroll AJ; Heerema NA; Devidas M; Dreyer ZE; Hilden JM; Hunger SP; Willman CL; Borden KLB; Felix CA
Oncogene; 2019 Mar; 38(13):2241-2262. PubMed ID: 30478448
[TBL] [Abstract][Full Text] [Related]
9. Molecular targeting of the UDP-glucuronosyltransferase enzymes in high-eukaryotic translation initiation factor 4E refractory/relapsed acute myeloid leukemia patients: a randomized phase II trial of vismodegib, ribavirin with or without decitabine.
Assouline S; Gasiorek J; Bergeron J; Lambert C; Culjkovic-Kraljacic B; Cocolakis E; Zakaria C; Szlachtycz D; Yee K; Borden KLB
Haematologica; 2023 Nov; 108(11):2946-2958. PubMed ID: 36951168
[TBL] [Abstract][Full Text] [Related]
10. Ribavirin suppresses eIF4E-mediated oncogenic transformation by physical mimicry of the 7-methyl guanosine mRNA cap.
Kentsis A; Topisirovic I; Culjkovic B; Shao L; Borden KL
Proc Natl Acad Sci U S A; 2004 Dec; 101(52):18105-10. PubMed ID: 15601771
[TBL] [Abstract][Full Text] [Related]
11. Targeting translation: eIF4E as an emerging anticancer drug target.
Lu C; Makala L; Wu D; Cai Y
Expert Rev Mol Med; 2016 Jan; 18():e2. PubMed ID: 26775675
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of eIF4E with ribavirin cooperates with common chemotherapies in primary acute myeloid leukemia specimens.
Kraljacic BC; Arguello M; Amri A; Cormack G; Borden K
Leukemia; 2011 Jul; 25(7):1197-200. PubMed ID: 21455212
[No Abstract] [Full Text] [Related]
13. A phase I trial of ribavirin and low-dose cytarabine for the treatment of relapsed and refractory acute myeloid leukemia with elevated eIF4E.
Assouline S; Culjkovic-Kraljacic B; Bergeron J; Caplan S; Cocolakis E; Lambert C; Lau CJ; Zahreddine HA; Miller WH; Borden KL
Haematologica; 2015 Jan; 100(1):e7-9. PubMed ID: 25425688
[No Abstract] [Full Text] [Related]
14. Dual targeting of eIF4E by blocking MNK and mTOR pathways in leukemia.
Kosciuczuk EM; Saleiro D; Platanias LC
Cytokine; 2017 Jan; 89():116-121. PubMed ID: 27094611
[TBL] [Abstract][Full Text] [Related]
15. Targeting eIF4E signaling with ribavirin as a sensitizing strategy for ovarian cancer.
Jin J; Xiang W; Wu S; Wang M; Xiao M; Deng A
Biochem Biophys Res Commun; 2019 Mar; 510(4):580-586. PubMed ID: 30739792
[TBL] [Abstract][Full Text] [Related]
16. Ribavirin treatment effects on breast cancers overexpressing eIF4E, a biomarker with prognostic specificity for luminal B-type breast cancer.
Pettersson F; Yau C; Dobocan MC; Culjkovic-Kraljacic B; Retrouvey H; Puckett R; Flores LM; Krop IE; Rousseau C; Cocolakis E; Borden KL; Benz CC; Miller WH
Clin Cancer Res; 2011 May; 17(9):2874-84. PubMed ID: 21415224
[TBL] [Abstract][Full Text] [Related]
17. The eIF4E inhibitor ribavirin as a potential antilymphoma therapeutic: early clinical data.
Rutherford SC; Stewart EN; Chen Z; Chadburn A; Wehrli NE; van Besien K; Martin P; Furman RR; Leonard JP; Cerchietti L
Leuk Lymphoma; 2018 Jan; 59(1):256-258. PubMed ID: 28573908
[No Abstract] [Full Text] [Related]
18. Ribavirin augments doxorubicin's efficacy in human hepatocellular carcinoma through inhibiting doxorubicin-induced eIF4E activation.
Tan J; Ye J; Song M; Zhou M; Hu Y
J Biochem Mol Toxicol; 2018 Jan; 32(1):. PubMed ID: 29112301
[TBL] [Abstract][Full Text] [Related]
19. Signalling to eIF4E in cancer.
Siddiqui N; Sonenberg N
Biochem Soc Trans; 2015 Oct; 43(5):763-72. PubMed ID: 26517881
[TBL] [Abstract][Full Text] [Related]
20. Initiation of mRNA translation in oncogenesis: the role of eIF4E.
Montanaro L; Pandolfi PP
Cell Cycle; 2004 Nov; 3(11):1387-9. PubMed ID: 15492504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]